FDA will delay Moderna use for children 12 to 17 to evaluate myocarditis risk until at least January | Daily Mail Online

Moderna says FDA will delay its vaccine use for children aged 12 to 17 to continue evaluations of myocarditis risk - or inflammation of the heart muscle - until at least January 2022.